[Use study of tenofovir DF in highly active anti-retroviral therapy]. / Estudio de utilización de Tenofovir DF en el tratamiento antirretroviral de gran actividad.
An Med Interna
; 23(12): 573-6, 2006 Dec.
Article
en Es
| MEDLINE
| ID: mdl-17371144
ABSTRACT
OBJECTIVE:
Describe the efficacy and safety of tenofovir.METHODS:
Observational, descriptive study. Data were analyzed for the intention-to-treat sample. The primary efficacy end-point included the proportion of patients with HIV-1 RNA level of 50 copies/ml or less. Secondary efficacy end points was the increase of the CD4 cell count at week 48. The primary safety end-point was the number of patients with abnormalities (clinical adverse events and laboratory toxicities). The causality of the adverse effects was measured by the Naranjo algorithm.RESULTS:
154 subjects were enrolled; 12 were excluded from all analyses. Efficacy end points Plasma HIV-1 RNA response -1.29 +/- 0.97 log10 copies/ml; Patients with HIV-1 RNA levels of 50 copies/ml or less 28.16%; CD4 cell count response 40.27 +/- 141.50 cel/mm3. Safety profile was similar to showed at prescribing information, 3 Fanconi Syndrome were detected.CONCLUSION:
Tenofovir supposes an antiretroviral of high effectiveness in our hospital, with an optimum safety profile.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Adenina
/
Síndrome de Inmunodeficiencia Adquirida
/
Fármacos Anti-VIH
/
Terapia Antirretroviral Altamente Activa
/
Organofosfonatos
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Es
Revista:
An Med Interna
Asunto de la revista:
MEDICINA INTERNA
Año:
2006
Tipo del documento:
Article